Natural estrogen/progesterone HT capsule shows promise

Article

A first-of-its-kind capsule combining natural 17β-estradiol and progesterone has promise for menopause-related hot flushes, according to results of a Phase 3 multi center trial.

A first-of-its-kind capsule combining natural 17β-estradiol and progesterone has promise for menopause-related hot flushes, according to results of a Phase 3 multicenter trial presented at the 65th Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists in San Diego. If approved, the product may provide an option for women in the United States who are currently using unregulated, unapproved, compounded bioidentical hormone replacement therapy (HRT).

Researchers from Eastern Virginia Medical School, conducted the REPLENISH study in 1,847 women with intact uteri. A total of 767 were randomized to 1 of 4 daily doses of TX-001HR (estradiol 1.0 mg/progesterone 100 mg, 0.5 mg/100 mg, 0.5 mg/50 mg, or 02.5 mg/50 mg) or placebo for 12 months.  The other 1,080 women were randomly assigned between the active treatments. Change from baseline to weeks 4 and 12 in frequency and severity of moderate to severe vasomotor symptoms was the primary efficacy endpoint. Endometrial hyperplasia at 12 months as the primary safety endpoint.

TX-001Hr 1.0 mg/100 mg and 0.5 mg/100 mg significantly improved the frequency and severity of moderate to severe hot flushes at weeks 4 (P < 0.05) and 12 (P < 0.05) versus placebo whereas 0.25 mg/50 mg significantly improved frequency but not severity of hot flushes. With all 4 doses and placebo after 12 months of therapy, incidence of endometrial hyperplasia or malignancy was 0%. All 4 TX-001HR doses were associated with a high incidence of amenorrhea.

Archer DF, Graham S, Gasper G, et al. REPLENISH trial: Combination capsule of estradiol/progesterone (TX-001HR) for treating hot flushes. Abstract 5M. Presented Monday, May 8 at the 65th Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists in San Diego, California. 

Recent Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Navigating vasomotor symptoms in breast cancer patients | Image Credit: menopausefoundationcanada.ca.
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
How to manage bone health in midlife women | Image Credit: - endocrine.org
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit: nursebarb.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.